3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
42
Urinary Bladder Neoplasms
18
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
11
Triple Negative Breast Neoplasms
10
Neoplasm Metastasis
10
Nasopharyngeal Carcinoma
10
Breast Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
9
Fallopian Tube Neoplasms
9
Lung Neoplasms
8
Carcinoma, Transitional Cell
8
Biliary Tract Neoplasms
7
Recurrence
6
Gallbladder Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
4
Urothelial Cancer
3
Stomach Neoplasms
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Adenocarcinoma
2
Non Small Cell Lung Carcinoma NSCLC
2
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gemcitabine
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled